|
**Overview**: Kappa Lambda Free Light Chain Urine Panel**Introduction**: The Kappa Lambda Free Light Chain Urine Panel is a diagnostic tool designed to assess urinary free light chains using urine samples. In India, urinary free light chains (uFLC) complement serum testing in multiple myeloma, especially light-chain-only or renal-impairing disease, with higher sensitivity for Bence Jones proteinuria detection. High morbidity from under-testing in rural/low-SES myeloma patients with proteinuria or renal failure, limited urine assays, delayed therapy leading to irreversible kidney damage. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for kappa and lambda free light chains over 1-2 days with high accuracy, valuable for monitoring light-chain excretion and treatment response. This diagnostic falls under protein screening and targets myeloma patients with renal involvement or light-chain disease, addressing accurate detection to guide chemotherapy and renal support. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise urinary light chain assessment and reducing myeloma-related renal complications. Its urine-based approach ensures reliable excretion evaluation.**Other Names**: Kappa Lambda U Pnl.**FDA Status**: FDA approved, CLIA certified for clinical pathology/immunology, compliant with 2025 standards.**Historical Milestone**: uFLC assay standard; in India, used in myeloma monitoring.**Purpose**: The test assesses 2 parameters including kappa free light chain to guide urinary light chain evaluation, detect Bence Jones proteinuria, inform monitoring.**Test Parameters**: 1. Kappa Free Light Chain, 2. Lambda Free Light Chain.**Pretest Condition**: No fasting required; patients should have suspected myeloma or proteinuria.**Specimen**: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on renal function, proteinuria, bone pain.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed light-chain disease including renal failure, benefits of screening, and minimal discomfort from urine collection.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or dilute urine can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated urinary light chains indicate active disease, necessitating specialist input.**Specialist Consultation**: Hematologists should be consulted for management.**Additional Supporting Tests**: Serum FLC, UPEP for confirmation.**Test Limitations**: Urine concentration variable; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Myeloma Studies India 2023. |
